Your browser doesn't support javascript.
loading
The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies.
Nelson, Michelle H; Fritzell, Sara; Miller, Robert; Werchau, Doreen; Van Citters, Danielle; Nilsson, Anneli; Misher, Lynda; Ljung, Lill; Bader, Robert; Deronic, Adnan; Chunyk, Allison G; Schultz, Lena; Varas, Laura A; Rose, Nadia; Håkansson, Maria; Gross, Jane; Furebring, Christina; Pavlik, Peter; Sundstedt, Anette; Veitonmäki, Niina; Ramos, Hilario J; Säll, Anna; Dahlman, Anna; Bienvenue, David; von Schantz, Laura; McMahan, Catherine J; Askmyr, Maria; Hernandez-Hoyos, Gabriela; Ellmark, Peter.
Afiliação
  • Nelson MH; Aptevo Therapeutics Inc., Seattle, Washington.
  • Fritzell S; Alligator Bioscience AB, Lund, Sweden.
  • Miller R; Aptevo Therapeutics Inc., Seattle, Washington.
  • Werchau D; Alligator Bioscience AB, Lund, Sweden.
  • Van Citters D; Aptevo Therapeutics Inc., Seattle, Washington.
  • Nilsson A; Alligator Bioscience AB, Lund, Sweden.
  • Misher L; Aptevo Therapeutics Inc., Seattle, Washington.
  • Ljung L; Alligator Bioscience AB, Lund, Sweden.
  • Bader R; Aptevo Therapeutics Inc., Seattle, Washington.
  • Deronic A; Alligator Bioscience AB, Lund, Sweden.
  • Chunyk AG; Aptevo Therapeutics Inc., Seattle, Washington.
  • Schultz L; Alligator Bioscience AB, Lund, Sweden.
  • Varas LA; Alligator Bioscience AB, Lund, Sweden.
  • Rose N; Saromics Biostructures AB, Lund, Sweden.
  • Håkansson M; Saromics Biostructures AB, Lund, Sweden.
  • Gross J; Aptevo Therapeutics Inc., Seattle, Washington.
  • Furebring C; Alligator Bioscience AB, Lund, Sweden.
  • Pavlik P; Aptevo Therapeutics Inc., Seattle, Washington.
  • Sundstedt A; Alligator Bioscience AB, Lund, Sweden.
  • Veitonmäki N; Alligator Bioscience AB, Lund, Sweden.
  • Ramos HJ; Aptevo Therapeutics Inc., Seattle, Washington.
  • Säll A; Alligator Bioscience AB, Lund, Sweden.
  • Dahlman A; Alligator Bioscience AB, Lund, Sweden.
  • Bienvenue D; Aptevo Therapeutics Inc., Seattle, Washington.
  • von Schantz L; Alligator Bioscience AB, Lund, Sweden.
  • McMahan CJ; Aptevo Therapeutics Inc., Seattle, Washington.
  • Askmyr M; Alligator Bioscience AB, Lund, Sweden.
  • Hernandez-Hoyos G; Aptevo Therapeutics Inc., Seattle, Washington.
  • Ellmark P; Alligator Bioscience AB, Lund, Sweden.
Mol Cancer Ther ; 22(1): 89-101, 2023 01 03.
Article em En | MEDLINE | ID: mdl-36343381
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Biespecíficos / Anticorpos de Cadeia Única / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Mol Cancer Ther Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Biespecíficos / Anticorpos de Cadeia Única / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Mol Cancer Ther Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2023 Tipo de documento: Article